2020 Virtual ESMO Review

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

2020 Virtual ESMO Review

Videos
Event

Playback speed

10 seconds

2020 ESMO Update on ALK+ NSCLC: PFS Data With Lorlatinib vs. Crizotinib - Should We Consider Lorlatinib a New 1L Option?

By 2020 Virtual ESMO Review FEATURING Ibiayi Dagogo-Jack

233 views

November 11, 2020

0 Comments

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Videos

2020 ESMO Update on R/R DLBCL: Does AUTO3 + Pembro Induce CRs? What …

2020 Virtual ESMO Review

J. Amengual

19 views

2020 ESMO Update on R/R cHL: How Effective Is Brentuximab Vedotin?

2020 Virtual ESMO Review

J. Amengual

55 views

2020 ESMO Update on Non-Hodgkin Lymphomas: Does BETi CC-90010 Lead t…

2020 Virtual ESMO Review

J. Amengual

17 views

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Sug…

2020 Virtual ESMO Review

I. Dagogo-Jack

177 views

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

2020 Virtual ESMO Review

I. Dagogo-Jack

29 views

2020 ESMO Update on UC: Does 1L Durvalumab +/- Tremelimumab Improve …

2020 Virtual ESMO Review

M. Bupathi

47 views

2020 ESMO Update on RCC: Is IO + TKI Option Effective in Advanced Di…

2020 Virtual ESMO Review

M. Bupathi

213 views

2020 ESMO Update on Advanced UC: Does the Addition of Avelumab 1L Ma…

2020 Virtual ESMO Review

M. Bupathi

74 views

2020 ESMO Update on ALK+ NSCLC: PFS Data With Lorlatinib vs. Crizoti…

2020 Virtual ESMO Review

I. Dagogo-Jack

233 views

ESMO 2020 Update on mPC: How Beneficial Is Abiraterone+/-Ipatasertib…

2020 Virtual ESMO Review

T. Barauskas Dorff

85 views

Will COVID-19 Leave Its Mark on Cancer Care?

Total Health

G. Lopes

1.8K views

2020 ESMO Updates on Pembrolizumab & Cemiplimab: Can mNSCLC Be Cured…

2020 Virtual ESMO Review

M. Dietrich

599 views

2020 ESMO First Results from PIONeeR Project on Biomarkers in Advanc…

2020 Virtual ESMO Review

M. Dietrich

515 views

2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost…

2020 Virtual ESMO Review

M. Dietrich

616 views

2020 ESMO Update on MBC: Is There OS Benefit to Alpelisib + Fulvestr…

2020 Virtual ESMO Review

J. Crozier

121 views

2020 ESMO Update on MBC: Does the Addition of Tamoxifen to Abemacicl…

2020 Virtual ESMO Review

J. Crozier

523 views

2020 ESMO Update on Immune Checkpoint Inhibitors in eTNBC: Does the …

2020 Virtual ESMO Review

L. Schwartzberg

379 views

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: Does the Add…

2020 Virtual ESMO Review

L. Schwartzberg

184 views

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: How Does Two…

2020 Virtual ESMO Review

L. Schwartzberg

200 views

2020 ESMO Update on mPDAC: Does the Addition of Dual Immune Checkpoi…

2020 Virtual ESMO Review

L. Connell

229 views

2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the Qoli…

2020 Virtual ESMO Review

L. Connell

64 views